Scarica l'app Stockscreener
28.71
1.17%
-0.34
Dopo l'orario di chiusura:
28.71
Maze Therapeutics Inc Borsa (MAZE) Ultime notizie
Does Maze Therapeutics Inc have declining or rising EPS2026 Sector Moves & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors. - Yahoo Finance
Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors. - The Motley Fool
Harold Bernstein Sells 15,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - MarketBeat
Insider Selling: Maze Therapeutics (NASDAQ:MAZE) SVP Sells 2,500 Shares of Stock - MarketBeat
Maze Therapeutics (MAZE) executive exercises options and sells 15,000 shares - Stock Titan
Maze Therapeutics (MAZE) SVP sells 2,500 shares after option exercise - Stock Titan
Washington University Purchases 70,121 Shares of Maze Therapeutics, Inc. $MAZE - MarketBeat
Maze Therapeutics shares surge after positive Phase 2 data for MZE829 - MSN
Atul Dandekar, CSBO of Maze Therapeutics, sells $220k in Maze stock - Investing.com
Maze Therapeutics (MAZE) CSBO exercises options and sells 7,500 shares - Stock Titan
Paradigm group holds 6.1% of Maze Therapeutics (NASDAQ: MAZE) in Schedule 13G - Stock Titan
Director at Maze (NASDAQ: MAZE) receives 33,417 stock options grant - Stock Titan
Maze Therapeutics (MAZE) director Neil Kumar submits initial Form 3 - Stock Titan
JPMorgan Chase & Co. Boosts Maze Therapeutics (NASDAQ:MAZE) Price Target to $58.00 - marketbeat.com
Maze Therapeutics, Inc. (MAZE) Gets a Buy from LifeSci Capital - The Globe and Mail
MAZE SEC FilingsMaze Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
Maze Therapeutics (MAZE) price target increased by 19.51% to 61.71 - MSN
Maze Therapeutics (NASDAQ:MAZE) Upgraded by Wall Street Zen to Hold Rating - marketbeat.com
Support Test: Is Maze Therapeutics Inc forming bullish engulfing patterns2026 Highlights & Verified Momentum Watchlists - baoquankhu1.vn
Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop (NASDAQ:MAZE) - Seeking Alpha
After a 30.8% Drop Over the Past Four Weeks, Here’s What Could Cause Maze Therapeutics, Inc. (MAZE) to Rebound - Bitget
After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE) - Yahoo Finance
Q1 EPS Forecast for Maze Therapeutics Raised by Analyst - MarketBeat
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), Maze Therapeutics, Inc. (MAZE) and Daiichi Sankyo Company (OtherDSKYF) - The Globe and Mail
What date does Maze Therapeutics, Inc.'s (MAZE) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
Dow Surges Over 300 Points; Chewy Shares Jump On Upbeat Earnings - Sahm
Maze Therapeutics Stock Falls Despite Strong Phase 2 Kidney Drug Data For MZE829 - Sahm
Encouraging HORIZON Phase 2 Data and Favorable Safety Support Buy Rating on Maze’s APOL1 Inhibitor MZE829 - TipRanks
Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 5.5% Following Earnings Beat - marketbeat.com
MAZE Shareholders Are Encouraged to Reach Out to Johnson - GlobeNewswire
Maze Therapeutics (NASDAQ:MAZE) Given New $110.00 Price Target at HC Wainwright - Defense World
Maze Therapeutics 2025 Annual Report: Pipeline, Strategy, and Clinical Program Overview - Minichart
Decoding Maze Therapeutics Inc (MAZE): A Strategic SWOT Insight - GuruFocus
Maze Therapeutics Executive Sells All Shares Ahead of Q4 Earnings Report - Intellectia AI
MAZE Stock Rating Reiterated by BTIG with $46 Price Target | MAZ - GuruFocus
Top 1% Biotech Crashes Despite 'Overwhelmingly Positive' Data - Investor's Business Daily
Maze Therapeutics reports Q4 EPS (65c), consensus (78c) - TipRanks
Maze Therapeutics Shares Phase II HORIZON Data: MZE829 Cuts Proteinuria in APOL1 Kidney Disease - marketbeat.com
Maze Therapeutics stock rating held at Buy by TD Cowen on trial data - Investing.com UK
Maze Therapeutics stock rating held at Buy by TD Cowen on trial data By Investing.com - Investing.com Australia
Maze Therapeutics share sell-off an ‘overreaction,’ says Raymond James - TipRanks
Maze Therapeutics' (MAZE) "Buy" Rating Reiterated at BTIG Research - marketbeat.com
BTIG reiterates Maze Therapeutics stock rating on trial results By Investing.com - Investing.com Canada
BTIG reiterates Maze Therapeutics stock rating on trial results - Investing.com
Maze Therapeutics falls despite positive mid-stage trial data for lead asset - MSN
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Maze Therapeutics (NASDAQ:MAZE) Shares Gap DownTime to Sell? - MarketBeat
Mizuho reiterates Maze Therapeutics stock rating on phase 2 data By Investing.com - Investing.com Australia
Maze Therapeutics stock rating reiterated at Strong Buy by Raymond James - Investing.com
Truist reiterates Buy on Maze Therapeutics stock after trial data By Investing.com - Investing.com Canada
Maze Therapeutics posts trial data for lead drug (MAZE:NASDAQ) - Seeking Alpha
HC Wainwright Raises Maze Therapeutics (NASDAQ:MAZE) Price Target to $110.00 - marketbeat.com
Maze Therapeutics shares are trading lower. T... - benzinga.com
MAZE Shattered: A 37% Plunge Marks a Major Trust Crisis in the Future of Biotech - Bitget
After ph. 2 readout, analysts herald 'best-in-class potential' for Maze kidney candidate as stock plummets - fiercebiotech.com
Mizuho reiterates Maze Therapeutics stock rating on phase 2 data - Investing.com
Leerink reiterates Maze Therapeutics stock rating on trial data By Investing.com - Investing.com Australia
Leerink reiterates Maze Therapeutics stock rating on trial data - Investing.com
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):